Insmed Incorporated (INSM) News
Track canonical SquawkNews coverage tagged to INSM, Insmed Incorporated. This hub brings together deduplicated headlines about nasdaq, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 25 indexed stories across 17 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
INSM - Insmed Expands Community Impact During Fifth Annual Global Day of Good
INSM - Insmed Expands Community Impact During Fifth Annual Global Day of Good
NEWS | Sep 16, 2026, 11:02 AM UTC
L
Insmed Price Target Cut to $198.00/Share From $212.00 by Roth Capital
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 04:51 PM UTC
H
INSM: BRINSUPRI's blockbuster launch and robust pipeline set the stage for sustained, multi-year growth
BRINSUPRI's launch has exceeded expectations, with first-year revenue estimates of $1.25—$1.4 billion and peak sales guidance raised above $7 billion. Expansion into COPD/asthma comorbid populations and international mar
EARNINGS | Sep 14, 2026, 08:01 PM UTC
H
INSM: BRINSUPRI's blockbuster launch and expanding pipeline set the stage for sustained high growth
BRINSUPRI's launch has exceeded expectations, with first-year revenue projected at $1.25—$1.4 billion and peak sales guidance raised above $7 billion. Expansion into comorbid COPD and asthma populations, strong internati
EARNINGS | Sep 14, 2026, 07:38 PM UTC
L
Insmed Director Sold Shares Worth Over $3.1M
David R. Brennan, a Director, reported a direct sale of 25,000 shares of Common Stock at $124.00 per share on September 9, 2026. The total reported sale amount was $3,100,000. Following the transaction, Brennan directly
EQUITY | Sep 11, 2026, 08:12 PM UTC
H
Insmed raises peak sales guidance to $14 billion
Insmed (INSM) raised peak sales guidance to $14 billion, citing strong BRINSUPRI and TPIP performance and expanding indications. It expects profitability next year.
EARNINGS | Sep 09, 2026, 02:06 PM UTC
H
INSM raises peak sales guidance to $14 billion across three products
INSM raised peak sales guidance to $14 billion across three products. BRINSUPRI and TPIP revisions were driven by strong launch metrics and expanded indications, with BRINSUPRI launch outperforming analogs.
EARNINGS | Sep 09, 2026, 01:40 PM UTC
L
Insmed announces inducement awards under Nasdaq Rule 5635(c)(4)
Insmed Incorporated announced the granting of inducement awards under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 11:00 AM UTC
L
Insmed reports inducement grants under NASDAQ Rule 5635(c)(4)
Insmed disclosed inducement grants under NASDAQ Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 11:00 AM UTC
H
INSM - Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspensi
INSM - Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congr
GEOPOLITICS | Sep 03, 2026, 11:01 AM UTC
L
Insmed set to present at September 2026 investor conferences
Insmed says it will present at September 2026 investor conferences, according to TradeXchange Newsdesk.
EQUITY | Aug 26, 2026, 11:01 AM UTC
M
INSM brensocatib approved in Japan for bronchiectasis
INSM says brinsupri (brensocatib) has been approved by Japan’s Ministry of Health, Labour and Welfare for patients with non-cystic fibrosis bronchiectasis.
REGULATION | Aug 24, 2026, 11:06 AM UTC
M
Insmed's Brinsupri wins Japan approval for bronchiectasis
Insmed says Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib) for patients with non-cystic fibrosis bronchiectasis.
REGULATION | Aug 24, 2026, 11:00 AM UTC
H
Alnylam cuts 2026 Amvuttra revenue guidance
Alnylam Pharmaceuticals cuts full-year 2026 revenue guidance for its Amvuttra franchise after early demand was inflated by a rush of pent-up patients.
EARNINGS | Aug 20, 2026, 04:03 PM UTC
H
Crude Oil Gains 2%; Keurig Dr Pepper Earnings Top Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 300 points on Thursday. The Dow traded down 0.63% to 54,005.27 while the NASDAQ fell 0.05% to 26,349.83. The S&P 500 also fell, dropp
EARNINGS | Aug 06, 2026, 04:04 PM UTC
H
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Motorola Solutions In c (NYSE: MSI ) rose sharply after the company reported better-than-expected second-quarter financial
EARNINGS | Aug 06, 2026, 02:01 PM UTC
H
Insmed Raises FY2026 Sales Guidance from $1.450B-$1.470B to $1.700B-$1.870B vs $1.705B Est
Insmed (NASDAQ: INSM ) raises FY2026 sales outlook from $1.450 billion-$1.470 billion to $1.700 billion-$1.870 billion vs $1.705 billion estimate.
EARNINGS | Aug 06, 2026, 11:07 AM UTC
L
INSM INSM - Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
INSM INSM - Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
EQUITY | Aug 06, 2026, 11:01 AM UTC
L
Near 50dma resistance SRE FLO LVS CSGP MSFT AAL TMUS ALLY HAYW VICI BIRK RKT INSM Z CSCO NKE STWD ZG DIS ESAB
Near 50dma resistance SRE FLO LVS CSGP MSFT AAL TMUS ALLY HAYW VICI BIRK RKT INSM Z CSCO NKE STWD ZG DIS ESAB
EQUITY | Jul 28, 2026, 03:56 PM UTC
L
INSM new Outperform W/ $192 PT @ BMO
INSM new Outperform W/ $192 PT @ BMO
EQUITY | Jul 21, 2026, 11:14 AM UTC
L
INSM Insmed - tpip demonstrates sustained improvement and reduced mortality risk at 12 months - Tpip safe and well-tolerated with no new saf
INSM Insmed - tpip demonstrates sustained improvement and reduced mortality risk at 12 months - Tpip safe and well-tolerated with no new safety signals through month 12
EQUITY | Jul 16, 2026, 11:02 AM UTC
L
INSM Insmed announces positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder (tpip) i
INSM Insmed announces positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder (tpip) in patients with pulmonary arterial hypertension
EQUITY | Jul 16, 2026, 11:00 AM UTC
L
Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing
() -- William Lewis, Director, Chair and CEO, on July 09, 2026, sold 10,699 shares in Insmed (INSM) for $1,256,084. Following the Form 4 filing with the SEC, Lewis has control over a total of 492,982 common shares of the
REGULATION | Jul 10, 2026, 08:08 PM UTC
L
Insmed Insider Sold Shares Worth $1,352,932, According to a Recent SEC Filing
() -- Martina Flammer, Chief Medical Officer, on July 06, 2026, sold 12,302 shares in Insmed (INSM) for $1,352,932. Following the Form 4 filing with the SEC, Flammer has control over a total of 60,486 common shares of th
REGULATION | Jul 08, 2026, 08:07 PM UTC
L
INSM Appoints New VP
Insmed appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
EQUITY | Jun 23, 2026, 11:01 AM UTC